MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.conctc.2020.100537

Медицинская библиотека · Contemporary clinical trials communications · 2020

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.

Hasan Alkomiet, Roeh Astrid, Leucht Stefan, Langguth Berthold, Hansbauer Maximilian, Oviedo-Salcedo Tatiana, Kirchner Sophie K, Papazova Irina, Löhrs Lisa, Wagner Elias, Maurus Isabel, Strube Wolfgang, Rossner Moritz J, Wehr Michael C, Bauer Ingrid, Heres Stephan, Leucht Claudia, Kreuzer Peter M, Zimmermann Stephanie, Schneider-Axmann Thomas, Görlitz Thomas, Karch Susanne, Egert-Schwender Silvia, Schossow Beate, Rothe Philipp, Falkai Peter

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model. As this signaling pathway is critically linked to the pathophysiology of schizophrenia, especially in the context of working-memory dysfunction, spironolactone may be a novel treatment option for patients with schizophrenia targeting cognitive impairments.

AIMS: To evaluate whether spironolactone added to an ongoing antipsychotic treatment improves cognitive functioning in schizophrenia.

METHODS

The add-on spironolactone for the treatment of schizophrenia trial (SPIRO-TREAT) is a multicenter randomized, placebo-controlled trial with three arms (spironolactone 100 mg, spironolactone 200 mg and placebo). Schizophrenia patients are treated for three weeks and then followed-up for additional nine weeks. As primary outcome, we investigate changes in working memory before and at the end of the intervention phase. We will randomize 90 patients. Eighty-one patients are intended to reach the primary endpoint measure at the end of the three-week intervention period. Secondary endpoints include other measures of cognition, psychopathology, safety measures and biological measures.

CONCLUSIONS

SPIRO-TREAT is the first study evaluating the efficacy of the mineralocorticoid receptor antagonist spironolactone to improve cognitive impairments in schizophrenia patients targeting the NRG1-ERBB4 signaling pathway. With SPIRO-TREAT, we intend to investigate a novel treatment option for cognitive impairments in schizophrenia that goes beyond the established concepts of interfering with dopaminergic neurotransmission as key pathway in schizophrenia treatment.

CLINICAL TRIAL REGISTRATION: International Clinical Trials Registry Platform: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-001968-35-DE.

Для цитирования: Hasan Alkomiet, Roeh Astrid, Leucht Stefan, Langguth Berthold, Hansbauer Maximilian, Oviedo-Salcedo Tatiana, Kirchner Sophie K, Papazova Irina, Löhrs Lisa, Wagner Elias, Maurus Isabel, Strube Wolfgang, Rossner Moritz J, Wehr Michael C, Bauer Ingrid, Heres Stephan, Leucht Claudia, Kreuzer Peter M, Zimmermann Stephanie, Schneider-Axmann Thomas, Görlitz Thomas, Karch Susanne, Egert-Schwender Silvia, Schossow Beate, Rothe Philipp, Falkai Peter. Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.. Contemporary clinical trials communications. 2020. DOI: 10.1016/j.conctc.2020.100537.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.